MoonLake Immunotherapeutics 8-K

What Happened

• On June 23, 2026 MoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC to sell securities in a public offering. The offering consists of 9,000,000 Class A ordinary shares at $20.00 per share (Firm Shares) and, in lieu of shares for certain investors, pre‑funded warrants to purchase up to 1,000,000 ordinary shares at $19.9999 per pre‑funded warrant. The pre‑funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The underwriters have a 30‑day option to buy up to an additional 1,500,000 shares. Gross proceeds are expected to be approximately $200 million before underwriting discounts and offering expenses. The offering is expected to close on June 25, 2026, subject to customary closing conditions.

Key Details

• Underwriter: Leerink Partners LLC (representative of the underwriters).
• Offer size: 9,000,000 shares + up to 1,000,000 pre‑funded warrants; 30‑day option for up to 1,500,000 additional shares.
• Price: $20.00 per share; $19.9999 per pre‑funded warrant; pre‑funded warrant exercise price $0.0001.
• Ownership limits: Exercise of pre‑funded warrants is limited so a holder’s beneficial ownership won’t exceed 4.99% (or 9.99% if elected); holders can increase that cap up to 19.99% with at least 61 days’ notice.
• Offering made under the company’s Form S‑3 shelf (File No. 333‑274286); final prospectus supplement filed June 24, 2026. Legal opinion from Walkers (Cayman) LLP was obtained and filed.

Why It Matters

• This transaction, if completed, will raise significant capital (about $200M gross) that the company can use for operations, development programs, R&D, or general corporate purposes. For current shareholders, the offering will increase the share count and may dilute existing ownership percentages. The availability of pre‑funded warrants and the ownership caps are important for investors monitoring potential voting/ownership impacts. Closing is subject to customary conditions, so investors should watch for completion and final share count (including whether the underwriters exercise their option).